Cargando…

Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion

INTRODUCTION: Trends on glycemic control and diabetes complications are known for high-income countries, but comprehensive data from low- and middle-income countries (LMIC) are lacking. METHODS: This is an expert opinion based on two retrospective studies. Here we examine the recent subset analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Aschner, Pablo, Galstyan, Gagik, Yavuz, Dilek G., Litwak, Leon, Gonzalez-Galvez, Guillermo, Goldberg-Eliaschewitz, Freddy, Hafidh, Khadija, Djaballah, Khier, Tu, Shih-Te, Unnikrishnan, Ambika G., Khunti, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099945/
https://www.ncbi.nlm.nih.gov/pubmed/33840067
http://dx.doi.org/10.1007/s13300-021-00997-0
_version_ 1783688677177688064
author Aschner, Pablo
Galstyan, Gagik
Yavuz, Dilek G.
Litwak, Leon
Gonzalez-Galvez, Guillermo
Goldberg-Eliaschewitz, Freddy
Hafidh, Khadija
Djaballah, Khier
Tu, Shih-Te
Unnikrishnan, Ambika G.
Khunti, Kamlesh
author_facet Aschner, Pablo
Galstyan, Gagik
Yavuz, Dilek G.
Litwak, Leon
Gonzalez-Galvez, Guillermo
Goldberg-Eliaschewitz, Freddy
Hafidh, Khadija
Djaballah, Khier
Tu, Shih-Te
Unnikrishnan, Ambika G.
Khunti, Kamlesh
author_sort Aschner, Pablo
collection PubMed
description INTRODUCTION: Trends on glycemic control and diabetes complications are known for high-income countries, but comprehensive data from low- and middle-income countries (LMIC) are lacking. METHODS: This is an expert opinion based on two retrospective studies. Here we examine the recent subset analysis of relevant data from the IDMPS Wave 7 (International Diabetes Management-Practices Study, 2015–2016) and the GOAL study conducted in multiple LMICs. RESULTS: Wave 7 sub-analysis was performed in 6113 people with type 2 diabetes from 24 LMIC. Poorly controlled diabetes (hemogloblin A1c [HbA1c] ≥ 7%) was found in 58.6, 73.0 and 78.3% of participants with diabetes duration of < 5, 5–12 and > 12 years, respectively (in association with a high prevalence of macro- and microvascular complications). Moreover, 37.7% of participants with diabetes duration of 5–12 years were treated only with oral antihyperglycemic drugs. The GOAL study investigated the efficacy of insulin in 2704 poorly controlled participants (mean HbA1c 9.7%; diabetes duration 10.1 ± 6.7 years; 10 LMIC). A significant 2% reduction in mean HbA1c levels was observed after 12 months of treatment. Only 7.2% of participants experienced a symptomatic episode of hypoglycemia (nocturnal or severe hypoglycemia events were infrequent). CONCLUSION: The rate of well-controlled participants (HbA1c < 7.0%) in the Wave 7 sub-analysis was lower than that observed in the USA (NHANES survey) or in European countries (GUIDANCE study), and the incidence of microvascular complications was higher. The GOAL study showed that insulin treatment improves glycemic control and reduces this gap. The Expert Panel recommends intensifying diabetes treatment as soon as possible, as well as patients’ education and other preventive measures, initiatives which require modest costs compared to hospitalization and treatment of diabetes complications.
format Online
Article
Text
id pubmed-8099945
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-80999452021-05-11 Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion Aschner, Pablo Galstyan, Gagik Yavuz, Dilek G. Litwak, Leon Gonzalez-Galvez, Guillermo Goldberg-Eliaschewitz, Freddy Hafidh, Khadija Djaballah, Khier Tu, Shih-Te Unnikrishnan, Ambika G. Khunti, Kamlesh Diabetes Ther Original Research INTRODUCTION: Trends on glycemic control and diabetes complications are known for high-income countries, but comprehensive data from low- and middle-income countries (LMIC) are lacking. METHODS: This is an expert opinion based on two retrospective studies. Here we examine the recent subset analysis of relevant data from the IDMPS Wave 7 (International Diabetes Management-Practices Study, 2015–2016) and the GOAL study conducted in multiple LMICs. RESULTS: Wave 7 sub-analysis was performed in 6113 people with type 2 diabetes from 24 LMIC. Poorly controlled diabetes (hemogloblin A1c [HbA1c] ≥ 7%) was found in 58.6, 73.0 and 78.3% of participants with diabetes duration of < 5, 5–12 and > 12 years, respectively (in association with a high prevalence of macro- and microvascular complications). Moreover, 37.7% of participants with diabetes duration of 5–12 years were treated only with oral antihyperglycemic drugs. The GOAL study investigated the efficacy of insulin in 2704 poorly controlled participants (mean HbA1c 9.7%; diabetes duration 10.1 ± 6.7 years; 10 LMIC). A significant 2% reduction in mean HbA1c levels was observed after 12 months of treatment. Only 7.2% of participants experienced a symptomatic episode of hypoglycemia (nocturnal or severe hypoglycemia events were infrequent). CONCLUSION: The rate of well-controlled participants (HbA1c < 7.0%) in the Wave 7 sub-analysis was lower than that observed in the USA (NHANES survey) or in European countries (GUIDANCE study), and the incidence of microvascular complications was higher. The GOAL study showed that insulin treatment improves glycemic control and reduces this gap. The Expert Panel recommends intensifying diabetes treatment as soon as possible, as well as patients’ education and other preventive measures, initiatives which require modest costs compared to hospitalization and treatment of diabetes complications. Springer Healthcare 2021-04-10 2021-05 /pmc/articles/PMC8099945/ /pubmed/33840067 http://dx.doi.org/10.1007/s13300-021-00997-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Aschner, Pablo
Galstyan, Gagik
Yavuz, Dilek G.
Litwak, Leon
Gonzalez-Galvez, Guillermo
Goldberg-Eliaschewitz, Freddy
Hafidh, Khadija
Djaballah, Khier
Tu, Shih-Te
Unnikrishnan, Ambika G.
Khunti, Kamlesh
Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title_full Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title_fullStr Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title_full_unstemmed Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title_short Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion
title_sort glycemic control and prevention of diabetic complications in low- and middle-income countries: an expert opinion
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099945/
https://www.ncbi.nlm.nih.gov/pubmed/33840067
http://dx.doi.org/10.1007/s13300-021-00997-0
work_keys_str_mv AT aschnerpablo glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT galstyangagik glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT yavuzdilekg glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT litwakleon glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT gonzalezgalvezguillermo glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT goldbergeliaschewitzfreddy glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT hafidhkhadija glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT djaballahkhier glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT tushihte glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT unnikrishnanambikag glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion
AT khuntikamlesh glycemiccontrolandpreventionofdiabeticcomplicationsinlowandmiddleincomecountriesanexpertopinion